Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 22, 2023
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 28, 2023
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2023
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 23, 2022
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2021
Lead Product(s) : Pyrotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyrotinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 20, 2021
Lead Product(s) : Pyrotinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial of SHR1258 in Patients With Biliary Tract Cancer
Details : SHR1258 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Biliary Tract Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 01, 2020
Lead Product(s) : Pyrotinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Details : Pyrotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 21, 2020
Lead Product(s) : Pyrotinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable